Drugs / XZ120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06206915 | Feb 2024 → Feb 2025 overdue | cancer | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZ120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06206915 ↗ |
| Route | Intravenous | “IV, no less than 60min” NCT06206915 ↗ |